Drug Profile
Glatiramer acetate controlled release - Mapi Pharma
Alternative Names: GA Depot; GA Depot injection; GA long-acting injection; Glatiramer acetate depot formulation - Mapi Pharma; Glatiramer acetate long-acting formulation - Mapi Pharma; Glatiramer acetate microspheresLatest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Mapi Pharma
- Class Peptides; Polymers
- Mechanism of Action Immunomodulators; MHC class II gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Multiple sclerosis
Most Recent Events
- 11 Mar 2024 Viatris and Mapi Pharma receives complete response letter from the US FDA for Glatiramer acetate controlled release in Multiple sclerosis
- 29 Feb 2024 Updated adverse events data and efficacy data from a phase III trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 (ACTRIMS-2024)
- 28 Oct 2023 No recent reports of development identified for research development in Multiple-sclerosis(Combination therapy) in Israel (IM, Controlled release)